Review: Tubulin function, action of antitubulin drugs, and new drug development

Cancer Investigation

Volumn 23, Issue 3, 2005, Pages 264-273

  Pellegrini, Federico ^a   Budman, Daniel R ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

Clinical pharmacology; Microtubulin dynamics

Indexed keywords

ALPHA TUBULIN; ANTINEOPLASTIC AGENT; ANTITUBULIN AGENT; BETA TUBULIN; BMS 184476; BMS 188797; BMS 275183; BMS 310705; COLCHICINE DERIVATIVE; COMBRETASTATIN A4; CYTOTOXIC AGENT; DJ 927; DOCETAXEL; EPOTHILONE B; EPOTHILONE DERIVATIVE; ESTRAMUSTINE; HMN 214; IDN 1509; IMATINIB; IXABEPILONE; KINESIN; LIPOSOME ENCAPSULATED PACLITAXEL; MICROTUBULE ASSOCIATED PROTEIN; MICROTUBULE PROTEIN; MICROTUBULIN; MOLECULAR MOTOR; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; N ACETYLCOLCHINOL PHOSPHATE; NAVELBINE; ORTATAXEL; PACLITAXEL; PACLITAXEL DERIVATIVE; PACLITAXEL POLIGLUMEX; PACLITAXEL TOCOSOL; PEGYLATED PACLITAXEL; PROTEIN HSEG5; PROTEIN KINASE INHIBITOR; PROTEIN POLO; RP 109881A; RPR 109881A; RPR 116258A; TAXANE DERIVATIVE; TAXOPREXIN; TUBULIN; UNCLASSIFIED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINDESINE; VINFLUNINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; BINDING SITE; CANCER CELL; CANCER CHEMOTHERAPY; COMBINATORIAL CHEMISTRY; COMPUTER AIDED DESIGN; CONCENTRATION RESPONSE; CYTOTOXICITY; DISSOCIATION CONSTANT; DRUG BINDING SITE; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROTUBULE ASSEMBLY; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; MICROTUBULES; TUBULIN; TUBULIN MODULATORS;

EID: 20044379059     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-200055970     Document Type: Review

References (147)

1. Budman, D.R. New vinca alkaloids and related compounds. Semin. Oncol. 1992, 19, 639-645.
2. Liu, X.M.; Wang, L.G.; Kreis, W.; Budman, D.R.; Adams, L.M. Differential effect of vinorelbine versus paclitaxel on ERK2 kinase activity during apoptosis in MCF-7 cells. Br. J. Cancer 2001, 55, 1403-1411.
3. Poruchynsky, M.S.; Wang, E.E.; Rudin, C.M.; Blagosklonny, M.V.; Fojo, T. Bcl-xL is phosphorylated in malignant cells following microtubule disruption. Cancer Res. 1998, 58, 3331-3338.
4. Valler, M.; Green, D. Diversity screening versus focussed screening in drug discovery. Drug Discov. Today 2000, 5, 286-293.
5. Dustin, P. Microtubules. Sci. Am. 1980, 243, 66-76.
6. Gundersen, G.G.; Cook, T. Microtubules and signal transduction. Curr. Opin. Cell Biol. 1999, 11, 81-94.
7. Verhey, K.; Rapoport, T. Kinesin carries the signal. Trends Biochem. Sci. 2001, 26, 545-550.
8. Galjart, N.; Perez, F. A plus-end raft to control microtubule dynamics and function. Curr. Opin. Cell Biol. 2003, 15, 48-53.
9. Wubbolts, R.; Fernandez-Borja, M.; Jordens, I.; Reits, E.; Dusseljee, S.; Echeverri, C.J.; Vallee, R.; Neefjes, J. Opposing motor activities of dynein and kinesin determine retention and transport of MHC class II-containing compartments. J. Cell. Sci. 1999, 112, 785-795.
10. Wittmann, T.; Hyman, A.; Desai, A. The spindle: a dynamic assembly of microtubules and motors. Nat. Cell Biol. 2001, 3, E28-E34.
11. Downing, K.; Nogales, E. New insights into microtubule structure and function from the atomic model of tubulin. Eur. Biophys. J. 1998, 27, 431-436.
12. Downing, K.; Nogales, E. Tubulin and microtubule structure. Curr. Opin. Cell Biol. 1998. 10, 16-22.
13. Zheng, Y.; Jung, M.K.; Oakley, B.R. Gamma-tubulin is present in Drosophila melanogaster and Homo sapiens and is associated with the centrosome. Cell 1991, 65, 817-823.
14. Chang, P.; Stearns, T. Delta-tubulin and epsilon-tubulin: two new human centrosomal tubulins reveal new aspects of centrosome structure and function. Nat. Cell Biol. 2000, 2, 30-35.
15. Luduena, R.F. Multiple forms of tubulin: different gene products and covalent modifications. Int. Rev. Cyt. 1998, 178, 207-275.
16. Roach, M.C.; Boucher, V.L.; Walss, C.; Ravdin, P.M.; Luduena, R.F. Preparation of a monoclonal antibody specific for the class I isotype of beta-tubulin: the beta isotypes of tubulin differ in their cellular distributions within human tissues. Cell Motil. Cytoskelet. 1998, 39, 273-285.
17. Lewis, S.A.; Gilmartin, M.E.; Hall, J.L.; Cowan, N.J. Three expressed sequences within the human beta-tubulin multigene family each define a distinct isotype. J. Mol. Biol. 1985, 182, 11-20.
18. Lewis, S.A.; Cowan, N.J. Complex regulation and functional versatility of mammalian alpha- and beta-tubulin isotypes during the differentiation of testis and muscle cells. J. Cell Biol. 1988, 106, 2023-2033.
19. Gundersen, G.G.; Khawaja, S.; Bulinski, J.C. Postpolymerization detyrosination of alpha-tubulin: a mechanism for subcellular differentiation of microtubules. J. Cell Biol. 1987, 105, 251-264.
20. Schulze, E.; Asai, D.J.; Bulinski, J.C.; Kirschner, M. Posttranslational modification and microtubule stability. J. Cell Biol. 1987, 105, 2167-2177.
21. Chang, P.; Giddings, T.J.; Winey, M.; Stearns, T. Epsilon-tubulin is required for centriole duplication and microtubule organization. Nat. Cell Biol. 2003, 5, 71-76.
22. Zhang, Y.; Li, N.; Caron, C.; Matthias, G.; Hess, D.; Khochbin, S.; Matthias, P. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J. 2003, 22, 1168-1179.
23. Carre, M.; Andre, N.; Carles, G.; Borghi, H.; Brichese, L.; Briand, C.; Braguer, D. Tubulin is an inherent component of mitochondrial membranes that interacts with the voltage-dependent anion channel. J. Biol. Chem. 2002, 277, 33664-33669.
24. Blagosklonny, M.V.; Fojo, T. Molecular effects of paclitaxel: myths and reality (a critical review). Int. J. Cancer 1999, 83, 151-156.
25. Bourgarel-Ray, V.; El Khyari, S.; Rimet, O.; Guigal, N.; Braguer, D.; Seree, E.; Barra, Y.; Briand, C. Opposite effects of antimicrotubule agents on c-myc oncogene expression depending on the cell lines used. Eur. J. Cancer 2000, 36, 1043-1049.
26. Amos, L.A.; Baker, T.S. The three-dimensional structure of tubulin protofilaments. Nature 1979, 279, 607-612.
27. Walker, R.A.; O'Brien, E.T.; Pryer, N.K.; Soboeiro, M.F.; Voter, W.A.; Erickson, H.P.; Salmon, E.D. Dynamic instability of individual microtubules analyzed by video light microscopy: rate constants and transition frequencies. J. Cell Biol. 1988, 107, 1437-1448.
28. Jordan, M.A.; Farrell, K.W. Differential radiolabeling of opposite microtubule ends: methodology, equilibrium exchange-flux analysis, and drug poisoning. Anal. Biochem. 1983, 130, 41-53.
29. Correia, J.J.; Lobert, S. Physiochemical aspects of tubulin-interacting antimitotic drugs. Curr. Pharm. Des. 2001, 7, 1213-1228.
30. Nogales, E. Structural insights into microtubule function. Annu. Rev. Biochem. 2000, 69, 277-302.
31. Penningroth, S.M.; Kirschner, M.W. Nucleotide binding and phosphorylation in microtubule assembly in vitro. J. Mol. Biol. 1977, 115, 643-673.
32. Panda, D.; Miller, H.P.; Wilson, L. Determination of the size and chemical nature of the stabilizing "cap" at microtubule ends using modulators of polymerization dynamics. Biochemistry 2002, 41, 1609-1617.
33. Muller-Reichert, T.; Chretien, D.; Severin, F.; Hyman, A.A. Structural changes at microtubule ends accompanying GTP hydrolysis: information from a slowly hydrolyzable analogue of GTP, guanylyl (alpha,beta) methylenediphosphonate. Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 3661-3666.
34. Mitchison, T.; Kirschner, M. Dynamic instability of microtubule growth. Nature 1984, 312, 237-242.
35. Erickson, H.P.; O'Brien, E.T. Microtubule dynamic instability and GTP hydrolysis. Annu. Rev. Biophys. Biomol. Struct. 1992, 21, 145-166.
36. Margolis, R.L.; Wilson, L. Microtubule treadmilling: what goes around comes around. BioEssays 1998, 20, 830-836.
37. Cassimeris, L. Accessory protein regulation of microtubule dynamics throughout the cell cycle. Curr. Opin. Cell Biol. 1999, 11, 134-141.
38. Jenkins, S.M.; Johnson, G.V. Microtubule/MAP-affinity regulating kinase (MARK) is activated by phenylarsine oxide in situ and phosphorylates tau within its microtubule-binding domain. J. Neurochem. 2000, 74, 1463-1468.
39. Poruchynsky, M.S.; Giannakakou, P.; Ward, Y.; Bulinski, J.C.; Telford, W.G.; Robey, R.W.; Fojo, T. Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism. Biochem. Pharmacol. 2001, 62, 1469-1480.
40. Mistry, S.; Atweh, G. Role of stathmin in the regulation of the mitotic spindle: potential applications in cancer therapy. Mt. Sinai J. Med. 2002, 69, 299-304.
41. Wood, K.; Cornwell, W.; Jackson, J. Past and future of the mitotic spindle as an oncology target. Curr. Opin. Cell Biol. 2001, 1, 370-377.
42. Giodini, A.; Kallio, M.J.; Wall, N.R.; Gorbsky, G.J.; Tognin, S.; Marchisio, P.C.; Symons, M.; Altieri, D.C. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res. 2002, 62, 2462-2467.
43. Alteri, D. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol. Med. 2001, 7, 542-547.
44. Krasenti, E.; Vernos, I. The mitotic spindle: a self-made machine. Science 2001, 294, 543-547.
45. Hait, W.N.; Rubin, E.; Goodin, S. Tubulin targeting agents. Cancer Chemother. Biol. Response Modif. 2001, 19, 59-83.
46. Dustin, P. The centennial of the discovery of the antimitotic properties of colchicine. Rev. Med. Brux. 1989, 10, 385-390.
47. Rowinsky, E.K.; Donehower, R.C. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol. Ther. 1991, 52, 35-84.
48. Lopes, N.; Miller, H.; Young, N.; Bhuyan, B. Assessment of microtubule stabilizers by semiautomated in vitro microtubule protein polymerization and mitotic block assays. Cancer Chemother. Pharmacol. 1997, 41, 37-47.
49. Roberge, M.; Cinel, B.; Anderson, H.; Lim, L.; Jiang, X.; Xu, L.; Bigg, C.; Kelly, M.; Anderson, R. Cell-based screen for antimitotic agents and identification of analogues of rhizoxin, eleutherobin, and paclitaxel in natural extracts. Cancer Res. 2000, 60, 5052-5058.
50. Shi, Q.; Chen, K.Y.; Morris-Natschke, S.; Lee, K. Recent progress in the development of tubulin inhibitors as antimitotic antitumor agents. Curr. Pharm. Des. 1998, 4, 219-248.
51. Dowlati, A.; Robertson, K.; Cooney, M.; Petros, W.P.; Stratford, M.; Jesberger, J.; Rafie, N.; Overmoyer, B.; Makkar, V.; Stambler, B.; Taylor, A.; Waas, J.; Lewin, J.S.; McCrae, K.R.; Remick, S.C. A phase 1 pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 2002, 62, 3408-3416.
52. Griggs, J.; Hesketh, R.; Smith, G.A.; Brindle, K.M.; Metcalfe, J.C.; Thomas, G.A.; Williams, E.D. Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue. Br. J. Cancer 2001, 84, 832-835.
53. Blakey, D.C.; Westwood, F.R.; Walker, M.; Hughes, G.D.; Davis, P.D.; Ashton, S.E.; Ryan, A.J. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin. Cancer Res. 2002, 8, 1974-1983.
54. Siemann, D.W.; Rojiani, A.M. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int. J. Radiat. Oncol. Biol. Phys. 2002, 55, 164-171.
55. Yoshimatsu, K.; Yamaguchi, A.; Yoshino, H.; Koyanagi, N.; Kitoh, K. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res. 1997, 57, 3208-3213.
56. Yamamoto, K.; Noda, K.; Yoshimura, A.; Fukuoka, M.; Furuse, K.; Niitani, H. Phase I study of E7010. Cancer Chemother. Pharmacol. 1998, 42, 127-134.
57. Campbell, K.; Hersh, E.; Stopeck, A.; Glennie, K.; GA, S.; Taylor, C.; Von Hoff, D. A phase I trial of ABI-007 administered weekly for three doses every 4 weeks in patients with advanced non-hematologic malignancies. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2002, 21, 403a.
58. Rose, W.C.; Fairchild, C.; Lee, F.Y. Preclinical antitumor activity of two novel taxanes. Cancer Chemother. Pharmacol. 2001, 47, 97-105.
59. Hidalgo, M.; Aylesworth, C.; Hammond, L.A.; Britten, C.D.; Weiss, G.; Stephenson, J., Jr.; Schwartz, G.; Patnaik, A.; Smith, L.; Molpus, K.; Felton, S.; Gupta, E.; Ferrante, K.J.; Tortora, A.; Sonnichsen, D.S.; Skillings, J.; Rowinsky, E.K. Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel. J. Clin. Oncol. 2001, 19, 2493-2503.
60. Plummer, R.; Ghielmini, M.; Calvert, P.; Voi, M.; Renard, J.; Gallamt, G.; Gupta, E.; Calvert, H.; Sessa, C. Phase I and pharmacokinetic study of the new taxane analog BMS-1884476 given weekly in patients with advanced malignancies. Clin. Cancer Res. 2002, 8, 2788-2797.
61. Advani, R.; Fisher, G.; Lum, B.L.; Jambalo, C.; Cho, C.D.; Cohen, M.; Gollererki, A.; Sikic, B.I. Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. Clin. Cancer Res. 2003, 9, 5187-5194.
62. Sullivan, D.; Dellaportas, A.; Mahany, J.; Kvols, L.; Rago, R.; Dinwoodie, W.; Lush, R.; Gallant, G.; et al. A phase I study of BMS-188797, a novel taxane, in combination with carboplatin administered every 21 days. Clin. Cancer Res. 2001, 11 (Suppl.), 786a.
63. Kadow, J.; Cook, D.; Du, K.; Hansel, S.; Johnson, W.; Mastalerz, H.; Schwanz, W.; Scola, P.; et al. The discovery of BMS-275183, a novel, orally bioavailable taxane for human clinical evaluation. Clin. Cancer Res. 2001, 7 (Suppl.), 771a.
64. Rose, W.C.; Long, B.H.; Fairchild, C.R.; Lee, F.Y.; Kadow, J.F. Preclinical pharmacology of BMS-275183, an orally active taxane. Clin. Cancer Res. 2001, 7, 2016-2021.
65. Todd, R.; Sludden, J.; Boddy, A.; Griffin, M.; Robson, L.; Cassidy, J.; Bisset, D.; Main, M.; et al. Phase I and pharmacological study of CT-2103, a poly (1-glutamic acid)-paclitaxel congugate. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2001, 20, 439a.
66. Shionoya, M.; Jimbo, T.; Kitagawa, M.; Soga, T.; Tohgo, A. DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo. Cancer Sci. 2003, 94, 459-466.
67. Soepenberg, O.; Sparrewboom, A.; de Jonge, M.; de Heus, G.; Paolini, J.; Angiuli, P.; Breda, M.; Bowden, C.; et al. Phase I and pharmacologic study of a weekly schedule of LEP (liposome encapsulated paclitaxel) in patients with solid tumors. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2002, 21, 404a.
68. Distefano, M.; Scambia, G.; Ferlini, C.; Gaggini, C.; De Vincenzo, R.; Riva, A.; Bombardelli, E.; Ojima, I.; Fattorossi, A.; Panici, P.B.; Mancuso, S. Anti-proliferative activity of a new class of taxanes (14beta-hydroxy-10- deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells. Int. J. Cancer 1997, 72, 844-850.
69. Ramnath, N.; Hamm, J.; Schwartz, G.; Eckhardt, G.; Bernacki, R.; Sutton, J.; Kaidbey, J.; Creaven, P. A phase I and pharmacokinetic study of a novel taxane BAY 59-8862. Clin. Cancer Res. 2001, 7 (Suppl.), 777a.
70. Beeram, M.; Rowinsky, E.; Hammond, L.; Patnaik, A.; Schwartz, G.; de Bono, J.; Forero, L.; Forouzesh, B.; et al. A phase I and pharmacokinetic study of PEG-paclitaxel in patients with advanced solid tumors. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2002, 21, 405a.
71. Sessa, C.; Cuvier, C.; Caldiera, S.; Bauer, J.; Van Den Bosch, S.; Monnerat, C.; Semiond, D.; Perard, D.; Lebecq, A.; Besenval, M.; Marty, M. Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors. Ann. Oncol. 2002, 13, 1140-1150.
72. Gelmon, K.A.; Latreille, J.; Tolcher, A.; Genier, L.; Fisher, B.; Forand, D.; D'Aloisio, S.; Vernillet, L.; Daigneault, L.; Lebecq, A.; Besenval, M.; Eisenhauer, E. Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors. J. Clin. Oncol. 2000, 18, 4098-4108.
73. Goetz, A.; Dennis, L.; Rowinsky, E.; Ochoa, L.; Molpus, K.; Deblonde, B.; Semiond, D.; Besenval, M. Phase I and pharmacokinetic study of RPR 11625 8A, a novel taxane derivative, administered over 1 hour every 3 weeks. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2001, 20, 419a.
74. Spigel, S.; Jones, S.; Greco, F.; Hainsworth, J.; Dickson, N.; Willcutt, N.; Calvert, S.; Pratt, J.; et al. S-8182 vitamin E paclitaxel emulsion: preclinical and phase I data. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2002, 21, 406a.
75. Harries, M.; O'Donnell, A.; Kaye, S.; Scurr, M.; Judson, I.; Reade, S.; Cole, C.; Twelves, C.; et al. Phase I/II study of taxoprexin (DHA-paclitaxel) in combination with carboplatin in patients with advanced malignancies. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2002, 2002, 400a.
76. Lee, F.Y.; Borzilleri, R.; Fairchild, C.R.; Kim, S.H.; Long, B.H.; Reventos-Suarez, C.; Vite, G.D.; Rose, W.C.; Kramer, R.A. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin. Cancer Res. 2001, 7, 1429-1437.
77. LoRusso, P.; Wozniak, A.; Flaherty, L.; Shields, A.; Wright, J.; Lebwohl, D. Phase I clinical trial of BMS-247550 (aka Epothilone B Analog; NSC710428) in adult patients with advanced solid tumors. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2001, 20, 215a.
78. Tripathi, R.; Gadgeel, S.; Wozniak, A.; Flaherty, L.; Shields, A.; Colevas, D.; Lebwohl, D.; LoRusso, P.; et al. Phase I clinical trial of BMS-247550 (epothilone B derivative) in adult patients with advanced solid tumors. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2002, 21, 407a.
79. Mekhail, T.; Holden, S.; Pierson, S.; Lee, F.; Galbraith, S.M.; Cohen, M.; Messina, M.; Roedig, B.; et al. A phase I pharmacokinetic and biologic study of the novel epothilone BMS-310705 in patients with advanced cancer. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2002, 21, 408a.
80. Calvert, P.; O'Neill, V.; Twelves, C.; Azzabi, A.; Hughes, A.; Bales, C.; Robinson, A.; Machan, M.; et al. A phase I clinical and pharmacokinetic study of EPO 906 (Epothilone B), given every three weeks. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2001, 20, 429a.
81. Kruczynski, A.; Hill, B.T. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Crit. Rev. Oncol./Hematol. 2001, 40, 159-173.
82. Ramnath, N.; Schwanz, G.; Booker, B.; Bong, D.; Smith, P.; Kanter, P.; Berdzik, J.; Creaven, P. A phase I and pharmacokinetic study of anhydrovinblastine. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2002, 21, 421a.
83. Ferrante, K.; Winograd, B.; Canetta, R. Promising new developments in cancer chemotherapy. Cancer Chemother. Pharmacol. 1999, 43, S61-S68.
84. Rowinsky, E.K.; Onetto, N.; Canetta, R.M.; Arbuck, S.G. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin. Oncol. 1992, 19, 646-662.
85. Kavallaris, M.; Verrills, N.M.; Hill, B.T. Anticancer therapy with novel tubulin-interacting drugs. Drug Resist. Updat. 2001, 4, 392-401.
86. Rao, S.; He, L.; Chakravarty, S.; Ojima, I.; Orr, G.A.; Horwitz, S.B. Characterization of the Taxol binding site on the microtubule. Identification of Arg(282) in beta-tubulin as the site of photoincorporation of a 7-benzophenone analogue of Taxol. J. Biol. Chem. 1999, 274, 37990-37994.
87. Wolff, J.; Knipling, L.; Cahnmann, H.; Palumbo, G. Direct photoaffinity labeling of tubulin with colchicine. Proc. Natl. Acad. Sci. U. S. A. 1991, 88, 2820-2824.
88. Rai, S.; Wolff, J. Localization of the vinblastine-binding site on beta-tubulin. J. Biol. Chem. 1996, 271, 14707-14711.
89. Chou, T.C.; Zhang, X.G.; Harris, C.R.; Kuduk, S.D.; Balog, A.; Savin, K.A.; Bertino, J.R.; Danishefsky, S.J. Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 15798-15802.
90. Muhlradt, P.F.; Sasse, F. Epothilone B stabilizes microtubuli of macrophages like taxol without showing taxol-like endotoxin activity. Cancer Res. 1997, 57, 3344-3346.
91. Altaha, R.; Fojo, T.; Reed, E.; Abraham, J. Epothilones: a novel class of non-taxane microtubule-stabilizing agents. Curr. Pharm. Des. 2002, 8, 1707-1712.
92. Altmann, K.H.; Wartmann, M.; O'Reilly, T. Epothilones and related structures-a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim. Biophys. Acta 2000, 1470, M79-M91.
93. Bollag, D.M.; McQueney, P.A.; Zhu, I.; Hensens, O.; Koupal, L.; Liesch, I.; Goetz, M.; Lazarides, E.; Woods, C.M. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 1995, 55, 2325-2333.
94. Kolman, A. Epothilone D (Kosan/Roche). Curr. Opin. Invest. Drugs 2004, 5, 657-667.
95. Giannakakou, P.; Gussio, R.; Nogales, E.; Downing, K.H.; Zaharevitz, D.; Bollbuck, B.; Poy, G.; Sackett, D.; Nicolaou, K.C.; Fojo, T. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 2904-2909.
96. Mulzer, J.; Mantoulidis, A.; Ohler, E. Total syntheses of epothilones B and D. J. Org. Chem. 2000, 65, 7456-7467.
97. Liu, Z.Y.; Chen, Z.C.; Yu, C.Z.; Wang, R.F.; Zhang, R.Z.; Huang, C.S.; Yan, Z.; Cao, D.R.; Sun, J.B.; Li, G. Total synthesis of epothilone A through stereospecific epoxidation of the p-methoxybenzyl ether of epothilone C. Chemistry 2002, 8, 3747-3756.
98. Laing, N.; Dahllof, B.; Hartley-Asp, B.; Ranganathan, S.; Tew, K.D. Interaction of estramustine with tubulin isotypes. Biochemistry 1997, 36, 871-878.
99. Horwitz, S.B.; Cohen, D.; Rao, S.; Ringel, I.; Shen, H.; Yang, C. Taxol: mechanisms of action and resistance. J. Natl. Cancer Inst. Monographs 1993, 15, 55-61.
100. Jordan, M.A.; Wendell, K.; Gardiner, S.; Derry, W. B.; Copp, H.; Wilson, L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res. 1996, 56, 816-825.
101. Wang, L.G.; Liu, X.M.; Kreis, W.; Budman, D.R. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother. Pharmacol. 1999, 44, 355-361.
102. Chaplin, D.J.; Pettit, G.R.; Parkins, C.S.; Hill, S.A. Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br. J. Cancer.. Suppl. 1996, 27, S86-S88.
103. Hayot, C.; Farinelle, S.; De Decker, R.; Decaestecker, C.; Darro, F.; Kiss, R.; Van Damme, M. In vitro pharmacological characterizations of the anti-angiogenic and anti-tumor cell migration properties mediated by microtubule-affecting drugs with specific emphasis on the organization of the actin cytoskeleton. Int. J. Oncol. 2002, 21, 417-425.
104. Moisoi, N.; Erent, M.; Whyte, S.; Martin, S.; Bayley, P.M. Calmodulin-containing substructures of the centrosomal matrix released by microtubule perturbation. J. Cell. Sci. 2002, 115, 2367-2379.
105. Wang, T.H.; Popp, D.M.; Wang, H.S.; Saitoh, M.; Mural, J.G.; Henley, D.C.; Ichijo, H.; Wimalasena, J. Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells. J. Biol. Chem. 1999, 274, 8208-8216.
106. Glass-Marmor, L.; Beitner, R. Taxol (paclitaxel) induces a detachment of phosphofructokinase from cytoskeleton of melanoma cells and decreases the levels of glucose 1.6-bisphosphate, fructose 1.6-bisphosphate and ATP. Eur. J. Pharmacol. 1999, 370, 195-199.
107. Giannakakou, P.; Sackett, D.L.; Ward, Y.; Webster, K.R.; Blagosklonny, M.V.; Fojo, T. p53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nat. Cell Biol. 2000, 2, 709-717.
108. Blagosklonny, M.V.; Giannakakou, P.; el-Deiry, W.S.; Kingston, D.G.; Higgs, P.I.; Neckers, L.; Fojo, T. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res. 1997, 57, 130-135.
109. Stewart, Z.A.; Tang, L.J.; Pietenpol, J.A. Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner. Oncogene 2001, 20, 113-124.
110. Blajeski, A.L.; Phan, V.A.; Kottke, T.J.; Kaufmann, S.H. G(1) and G(2) cell-cycle arrest following microtubule depolymerization in human breast cancer cells. J. Clin. Invest. 2002, 110, 91-99.
111. Giannakakou, P.; Robey, R.; Fojo, T.; Blagosklonny, M.V. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene 2001, 20, 3806-3813.
112. Chen, J.; Horwitz, S. Differential mitotic responses to microtubule-stabilizing and-destabilizing drugs. Cancer Res. 2002, 62, 1935-1938.
113. Giannakakou, P.; Nakano, M.; Nicolaou, K.C.; O'Brate, A.; Yu, J.; Blagosklonny, M.V.; Greber, U.F.; Fojo, T. Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics. Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 10855-10860.
114. Wang, T.H.; Wang, H.S.; Soong, Y.K. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 2000, 88, 2619-2628.
115. van Oosterom, A.T.; Schrijvers, D.; Schriivers, D. Docetaxel (Taxotere). a review of preclinical and clinical experience. Part II. Clinical experience. Anticancer Drugs 1995, 6, 356-368.
116. Farshori, P.Q.; Goode, D. Effects of the microtubule depolymerizing and stabilizing agents Nocodazole and taxol on glucose-induced insulin secretion from hamster islet tumor (HIT) cells. J. Submicrosc. Cytol. Pathol. 1994, 26, 137-146.
117. Huizing, M.T.; Misser, V.H.; Pieters, R.C.; ten Bokkel Huinink, W.W.; Veenhof, C.H.; Vermorken, J.B.; Pinedo, H.M.; Beijnen, J.H. Taxanes: a new class of antitumor agents. Cancer Investig. 1995, 13, 381-404.
118. Lobert, S.; Vulevic, B.; Correia, J.J. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine. Biochemistry 1996, 35, 6806-6814.
119. Chang, Y.H. Mechanism of action of colchicine. I. Effect of colchicine and its analogs on the reversed passive Arthus reaction and the carrageenan-induced hindpaw edema in the rat. J. Pharmacol. Exp. Ther. 1975, 194, 154-158.
120. Walss, C.; Kreisberg, J.I.; Luduena, R.F. Presence of the betaII isotype of tubulin in the nuclei of cultured mesangial cells from rat kidney. Cell Motil. Cytoskelet. 1999, 42, 274-284.
121. II-tubulin in tumor cells: a possible novel target for taxol. Cell Motil. Cytoskelet. 2002, 53, 39-52.
122. Yvon, A.M.; Wadsworth, P.; Jordan, M.A. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol. Biol. Cell 1999, 10, 947-959.
123. Derry, W.B.; Wilson, L.; Jordan, M.A. Low potency of taxol at microtubule minus ends: implicatins for its antimitotic and the-wraeputic mechanism. Cancer Res. 1998, 58, 1177-1184.
124. Snyder, J.P.; Nettles, J.H.; Cornett, B.; Downing, K.H.; Nogales, E. The binding conformation of Taxol in beta-tubulin: a model based on electron crystallographic density. Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 5312-5316.
125. He, L.; Orr, G.; Horowitz, S. Novel molecules that interact with microtubules and have functional activity similar to Taxol. Drug Discov. Today 2001, 22, 1153-1164.
126. Kar, S.; Fan, J.; Smith, M.; Goedert, M.; Amos, L. Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. EMBO J. 2003, 22, 70-77.
127. Panda, D.; Miller, H.P.; Islam, K.; Wilson, L. Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action. Proc. Natl. Acad. Sci. U. S. A. 1997, 94, 10560-10564.
128. Ling, Y.; Jiang, J.; Holland, J.; Perez-Soler, R. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol. Pharmacol. 2002, 62, 529-538.
129. Dumontet, C. Mechanisms of action and resistance to tubulin-binding agents. Expen Opin. Investig. Drugs 2000, 9, 779-788.
130. Burkhart, C.A.; Kavallaris, M.; Band Horwitz, S. The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim. Biophys. Acta 2001, 2, O1-O9.
131. Drukman, S.; Kavallaris, M. Microtubule alterations and resistance to tubulin-binding agents (Review). Int. J. Oncol. 2002, 21, 621-628.
132. Kavallaris, M.; Kuo, D.Y.; Burkhan, C.A.; Regl, D.L.; Norris, M.D.; Haber, M.; Horwitz, S.B. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J. Clin. Invest. 1997, 100, 1282-1293.
133. Kavallaris, M.; Tait, A.S.; Walsh, B.J.; He, L.; Horwitz, S.B.; Norris, M.D.; Haber, M. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res. 2001, 61, 5803-5809.
134. Kavallaris, M.; Burkhart, C.A.; Horwitz, S.B. Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol. Br. J. Cancer 1999, 80, 1020-1025.
135. Goncalves, A.; Braguer, D.; Kamath, K.; Martello, L.; Briand, C.; Horwitz, S.; Wilson, L.; Jordan, M.A. Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 11737-11742.
136. Zunino, F.; Cassinelli, G.; Polizzi, D.; Perego, P. Molecular mechanisms of resistance to taxanes and therapeutic implications. Drug Resist. Updat. 1999, 2, 351-357.
137. Giannakakou, P.; Poy, G.; Zhan, Z.; Knutsen, T.; Blagosklonny, M.; Fojo, T. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. Oncogene 2000, 19, 3078-3085.
138. Yang, H.; Horowitz, S. Mutations in beta-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines. Mol. Cancer Ther. 2001, 1, 3-10.
139. Bhalla, K.; Huang, Y.; Tang, C.; Self, S.; Ray, S.; Mahoney, M.E.; Ponnathpur, V.; Tourkina, E.; Ibrado, A.M.; Bullock, G.; et al. Characterization of a human myeloid leukemia cell line highly resistant to taxol. Leukemia 1994, 8, 465-475.
140. Rubenstein, S.M.; Baichwal, V.; Beckmann, H.; Clark, D.L.; Frankmoelle, W.; Roche, D.; Santha, E.; Schwender, S.; Thoolen, M.; Ye, Q.; Jaen, J.C. Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier. J. Med. Chem. 2001, 44, 3599-3605.
141. Efferth, T.; Fabry, U.; Osieka, R. Damage of the kinesin heavy chain gene contributes to the antagonism of cisplatin and paclitaxel. Anticancer Res. 2000, 20, 3211-3219.
142. Goldstein, L. Kinesin molecular motors: transport pathways, receptors, and human disease. Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 6999-7003.
143. Wood, K.; Beraud, C.; Chabala, J.; Crompton, A.; Finer, J.; Frisch, A.; Lee, Y.; Lewis, E.; et al. Inhibitors of the mitotic kinesin KSP: discovery and proof of principal anti-tumor activity. Proc. Am. Assoc. Cancer Res. 2002, 41, 3300a.
144. SC, H.; Vale, R.; Kuntz, I. Inhibitors of kinesin activity from structure-based computer screening. Biochemistry 2000, 39, 2805-2814.
145. Chu, Q.; Holen, K.; Rowinsky, E.; Alberti, D.; Monroe, P.; Volkman, J.; Hodge, J.; Sabry, J.; Ho, P.; Wilding, G. A phase I study to determine the safety and pharmacokinetics of IV administrated SB-715992, a novel kinesin spindle protein inhibitorm in patients with solid tumors. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2003, 22, 525a.
146. Patnaik, A.; Forero, L.; Goetz, A.; Tolcher, A.; Beeram, M.; De Bono, J.; Weiss, G.; Wood, L.; Takimoto, C.; Rowinsky, E. HMN-14, a novel oral antimicrotubular agent and inhibitor of polo-like and cyclin-dependent-kinases: clinical, pharmacokinetic and pharmacodynamic relationships observed in a phase I trial of a daily X 5 schedule every 28 days. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2003, 22, 514a.
147. Workman, P.; Kaye, S. Translating basic cancer research into new cancer therapeutics. Trends Mol. Med. 2002, 8 (Suppl.), s1-s9.